¼¼°èÀÇ ½Å°æ¾Æ¼¼Æ÷Á¾ Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð Á¶»ç : À¯Çüº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, Áö¿ªº°, ¿¹Ãø(2022-2032³â)
Global Neuroblastoma Drugs Market Size study, by Type (Chemotherapy, Immunotherapy, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Online, Offline), and Regional Forecasts 2022-2032
»óǰÄÚµå : 1498334
¸®¼­Ä¡»ç : Bizwit Research & Consulting LLP
¹ßÇàÀÏ : 2024³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,950 £Ü 6,894,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,250 £Ü 8,705,000
Printable PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

½Å°æ¾Æ¼¼Æ÷Á¾ Ä¡·áÁ¦ ¼¼°è ½ÃÀåÀº 2023³â ¾à 7¾ï 4,000¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, ¿¹Ãø ±â°£ÀÎ 2024³âºÎÅÍ 2032³â±îÁö 6.2% ÀÌ»óÀÇ °Ç°­ÇÑ ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½Å°æ¾Æ¼¼Æ÷Á¾Àº ÁÖ·Î 5¼¼ ÀÌÇÏÀÇ À¯¾Æ¿¡°Ô ¹ß»ýÇÏ´Â ¾ÏÀ¸·Î, ƯÈ÷ ½ÅÀå »óºÎ¿¡ À§Ä¡ÇÑ ºÎ½ÅÀÇ ½Å°æÁ¶Á÷¿¡¼­ ¹ß»ýÇÕ´Ï´Ù. ½Å°æ¾Æ¼¼Æ÷¶ó°í ºÒ¸®´Â ¹Ì¼º¼÷ÇÑ ½Å°æ¼¼Æ÷¿¡¼­ ¹ß»ýÇÏ¸ç ´Ù¾çÇÑ Áõ»ó°ú °á°ú¸¦ º¸ÀÌ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù. Áõ»óÀº º¹ºÎ µ¢¾î¸®, ÀåÀÇ ÆÐÅÏ º¯È­, »ÀÀÇ ºÒÆí°¨, ÇǷΰ¨, ÇǺΠº¯È­ µî ´Ù¾çÇÕ´Ï´Ù. ½Å°æ¾Æ¼¼Æ÷Á¾ Ä¡·áÁ¦´Â ½Å°æ¾Æ¼¼Æ÷Á¾°ú ½Î¿ì±â À§ÇØ Á¶Á¤µÈ ¾à¹°ÀÔ´Ï´Ù. ½Ã½ºÇöóƾÀ̳ª ¿¡ÅäÆ÷»çÀ̵å¿Í °°Àº È­Çпä¹ýÁ¦, ALK À¯ÀüÀÚ¸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â Å©¸®Á¶Æ¼´Õ°ú °°Àº Ç¥ÀûÄ¡·áÁ¦, µð´©Åö½Ã¸¿°ú °°Àº ¸é¿ª¿ä¹ý, ·¹Æ¼³ë»ê°ú °°Àº ºÐÈ­À¯µµÁ¦, i-131 MIBG¿Í °°Àº ¹æ»ç¼ºÀǾàǰÀÌ Æ÷ÇԵ˴ϴÙ. Ä¡·á °èȹÀº ¾ÏÀÇ º´±â, ȯÀÚÀÇ °Ç°­ »óÅ µîÀÇ ¿äÀο¡ µû¶ó °³º°È­µÇ¸ç, È¿°ú¸¦ ÃÖÀûÈ­Çϱâ À§ÇØ Àü¹®°¡ ÆÀÀÌ ¼³°èÇÑ Ä¡·á¹ý Á¶ÇÕÀ» Æ÷ÇÔÇÕ´Ï´Ù. °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿Í Ç¥Àû Ä¡·á·ÎÀÇ ÀüȯÀº ¼¼°è ½Å°æ¾Æ¼¼Æ÷Á¾ Ä¡·áÁ¦ ½ÃÀå¿¡¼­ Áß¿äÇÑ Ãß¼¼ÀÔ´Ï´Ù. ÀǾàǰ °³¹ßÀÚµéÀº ½Å°æ¾Æ¼¼Æ÷Á¾°ú °ü·ÃµÈ À¯ÀüÀÚ ÀÌ»óÀ̳ª »ý¹°ÇÐÀû °úÁ¤À» ƯÀÌÀûÀ¸·Î Ç¥ÀûÀ¸·Î »ï´Â ÀǾàǰ °³¹ß¿¡ ´õ¿í ÁýÁßÇϰí ÀÖ½À´Ï´Ù. ÀÌ ¹æ¹ýÀº º¸´Ù ÁýÁßÀûÀ̰í È¿À²ÀûÀÎ Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÏ¿© ºÎÀÛ¿ëÀ» ÁÙÀ̰í ȯÀÚ °á°ú¸¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ½Å°æ¾Æ¼¼Æ÷Á¾ Ä¡·áÁ¦ ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î´Â ÀÇ·á ±â¼úÀÇ ¹ßÀüÀ¸·Î ½Å°æ¾Æ¼¼Æ÷Á¾ ȯÀÚÀÇ Áø´Ü ¹× Ä¡·á ¿É¼ÇÀÌ °³¼±µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½Å°æ¾Æ¼¼Æ÷Á¾¿¡ ´ëÇÑ ÀÎ½Ä °³¼±°ú Á¶±â ¹ß°ß¿¡ ´ëÇÑ ³ë·ÂÀÌ ½Å°æ¾Æ¼¼Æ÷Á¾ Ä¡·áÁ¦ ¼ö¿ä¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Ç¥Àû Ä¡·á ¹× ¸é¿ª¿ä¹ý °³¹ß¿¡ ÃÊÁ¡À» ¸ÂÃá ¿¬±¸ °³¹ßÀÌ ÁøÇàµÇ°í ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Á¦¾à»çµéÀº ÀÌ Áúȯ¿¡ ´ëÇÑ º¸´Ù È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¹ÌÃæÁ· ¼ö¿ä¸¦ ÃæÁ·½Ã۱â À§ÇØ »õ·Î¿î ½Å°æ¾Æ¼¼Æ÷Á¾ Ä¡·áÁ¦ ¿¬±¸°³¹ß(R&D)¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿¬±¸°³¹ß Ȱµ¿ÀÇ È°¼ºÈ­·Î ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÒ ¼ö ÀÖ´Â ½Å°æ¾Æ¼¼Æ÷Á¾ ½Å¾àÀÌ °³¹ßµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¦¾à»ç, Çаè, ÀÇ·á ±â°ü °£ÀÇ Çù¾÷Àº Çõ½ÅÀ» ÃËÁøÇÏ°í »õ·Î¿î ½Å°æ¾Æ¼¼Æ÷Á¾ Ä¡·áÁ¦¸¦ ½ÃÀå¿¡ µµÀÔÇÔÀ¸·Î½á ÃßÁ¤ ±â°£ µ¿¾È ¼¼°è ½Å°æ¾Æ¼¼Æ÷Á¾ Ä¡·áÁ¦ ½ÃÀå¿¡ ´Ù¾çÇÑ ¼ºÀå Àü¸ÁÀ» °¡Á®´Ù ÁÙ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ±×·¯³ª ½Å°æ¾Æ¼¼Æ÷Á¾ Ä¡·áÁ¦¿Í °ü·ÃµÈ ºÎÀÛ¿ë°ú ÀǾàǰ ½ÂÀο¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°ÇÀº 2022³âºÎÅÍ 2032³â±îÁö ¼¼°è ½Å°æ¾Æ¼¼Æ÷Á¾ Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» ÀúÇØÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½Å°æ¾Æ¼¼Æ÷Á¾ Ä¡·áÁ¦ ¼¼°è ½ÃÀå Á¶»ç¿¡¼­ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀ¸·Î´Â ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä« ¹× ±âŸ Áö¿ªÀÌ Æ÷ÇԵǸç, 2023³â¿¡´Â ºÏ¹Ì°¡ ½Å°æ¾Æ¼¼Æ÷Á¾ Ä¡·áÁ¦ ½ÃÀå¿¡¼­ Áö¹èÀûÀÎ À§Ä¡¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â ½Å°æ¾Æ¼¼Æ÷Á¾ Ä¡·áÁ¦ÀÇ °¡¿ë¼º Áõ°¡, Á¤ºÎ Áö¿ø ÀÌ´Ï¼ÅÆ¼ºê, °­·ÂÇÑ ±ÔÁ¦ Áö¿ø ¹× È®¸³µÈ ÀÇ·á ½Ã½ºÅÛ°ú °°Àº ¿©·¯ ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. ¶ÇÇÑ, ÀÌ Áö¿ªÀº Á¦Ç° ½ÂÀÎ ¹× ÆÄÆ®³Ê½Ê°ú °°Àº Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê¿¡ Àû±ØÀûÀ¸·Î Âü¿©ÇÏ´Â ÁÖ¿ä ¾÷°è ±â¾÷ÀÇ Á¸Àç°¨ÀÌ Ä¿¼­ ºÏ¹Ì ½ÃÀå È®´ë¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÇÑÆí, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿¹Ãø ±â°£ µ¿¾È ±Þ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå ½Å°æ¾Æ¼¼Æ÷Á¾ Ä¡·áÁ¦ ¼¼°è ½ÃÀå Á¤ÀÇ¿Í Á¶»ç °¡Á¤

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½Å°æ¾Æ¼¼Æ÷Á¾ Ä¡·áÁ¦ ¼¼°è ½ÃÀå ¿ªÇÐ

Á¦4Àå ½Å°æ¾Æ¼¼Æ÷Á¾ Ä¡·áÁ¦ ¼¼°è ½ÃÀå »ê¾÷ ºÐ¼®

Á¦5Àå ½Å°æ¾Æ¼¼Æ÷Á¾ Ä¡·áÁ¦ ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : À¯Çüº°, 2022-2032³â

Á¦6Àå ½Å°æ¾Æ¼¼Æ÷Á¾ Ä¡·áÁ¦ ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Åõ¿© °æ·Îº°, 2022-2032³â

Á¦7Àå ½Å°æ¾Æ¼¼Æ÷Á¾ Ä¡·áÁ¦ ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : À¯Åë ä³Îº°, 2022-2032³â

Á¦8Àå ½Å°æ¾Æ¼¼Æ÷Á¾ Ä¡·áÁ¦ ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Áö¿ªº°, 2022-2032³â

Á¦9Àå °æÀï Á¤º¸

Á¦10Àå Á¶»ç °úÁ¤

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Neuroblastoma Drugs Market is valued approximately USD 740 million in 2023 and is anticipated to grow with a healthy growth rate of more than 6.2% over the forecast period 2024-2032. Neuroblastoma is a cancer primarily occurring in young children below five years old, originating in nerve tissue specifically in the adrenal glands atop the kidneys. It emerges from immature nerve cells, called neuroblasts, known for its diverse symptoms and outcomes. These range from abdominal lumps, altered bowel patterns, bone discomfort, fatigue, to skin alterations, showcasing its varied presentation. Neuroblastoma drugs are medications tailored to combat neuroblastoma. It encompasses chemotherapy agents like cisplatin and etoposide, targeted therapies such as crizotinib targeting the ALK gene, immunotherapies like dinutuximab, differentiation agents like retinoic acid, and radiopharmaceuticals like I-131 MIBG. Treatment plans are individualized based on factors like the cancer stage and patient's health involving a combination of therapies designed by a team of specialists to optimize effectiveness. The rising shift towards personalized medicine and targeted therapies is a key trend for the Global Neuroblastoma Drugs Market. Drug developers are concentrating more on creating medications that specifically target genetic abnormalities or biological processes associated with neuroblastoma. This method reduces adverse effects and enhances patient outcomes by enabling more focused and efficient therapy.

In addition, the key driving factors influencing the Neuroblastoma Drugs market include advancements in medical technology, leading to improved diagnosis and treatment options for neuroblastoma patients. Additionally, increased awareness about neuroblastoma and early detection initiatives contribute to the demand for neuroblastoma drugs. Moreover, ongoing research and development efforts focused on developing targeted therapies and immunotherapies further propel market growth. Pharmaceutical companies are heavily investing in research and development (R&D) of new neuroblastoma drugs to the unmet need for more effective treatments for this disease. As a result of this increased R&D activity, there are several new neuroblastoma drugs in the pipeline that have the potential to improve outcomes for patients. Furthermore, collaborations between pharmaceutical companies, academic institutions, and healthcare organizations foster innovation and the introduction of novel neuroblastoma drugs into the market, which are further presenting various growth prospects to the Global Neuroblastoma Drugs Market during the estimated period. However, adverse side effects associated with neuroblastoma drugs and stringent regulatory requirement for drug approvals are expected to stifle Global Neuroblastoma Drugs Market growth between 2022 and 2032.

The key regions considered for the global Neuroblastoma Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America held the dominant position in the neuroblastoma drugs market due to several factors such as rising availability of neuroblastoma drugs, supportive governmental initiatives, robust regulatory backing, and a well-established healthcare system. Moreover, the region benefits from the significant presence of key industry players that are actively engaged in strategic initiatives like product approvals and partnerships, contributing significantly to market expansion in North America. On the other hand, Asia Pacific is poised for rapid growth over the forecast period.

Major market player included in this report are:

The detailed segments and sub-segment of the market are explained below:

By Type

By Route of Administration

By Distribution Channel

By Region:

Years considered for the study are as follows:

Key Takeaways:

Table of Contents

Chapter 1. Global Neuroblastoma Drugs Market Definition and Research Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Neuroblastoma Drugs Market Dynamics

Chapter 4. Global Neuroblastoma Drugs Market Industry Analysis

Chapter 5. Global Neuroblastoma Drugs Market Size & Forecasts by Type 2022-2032

Chapter 6. Global Neuroblastoma Drugs Market Size & Forecasts by Route of Administration 2022-2032

Chapter 7. Global Neuroblastoma Drugs Market Size & Forecasts by Distribution Channel 2022-2032

Chapter 8. Global Neuroblastoma Drugs Market Size & Forecasts by Region 2022-2032

Chapter 9. Competitive Intelligence

Chapter 10. Research Process

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â